NOVEL ANTIBIOTICS DISCOVERY AND DRUG RESISTANCE REVISITED
AbstractDrug resistance in bacterial strains has often been detected in the last two decades and is increasing yearly. Novel survival mechanisms and over-the-counter antibiotic availability (OTC) complicated this issue, especially in relation to the Asian continent. Resistance to drug/antibiotic is multifactorial viz, plasmid encoding drug resistance, pumping the drug out by pumping mechanism from the bacterial cell, degradation of antibiotic by using enzymes such as β-lactamases, carbapenemase and others. Bacterial drug resistance is a global threat, and the discovery of novel antibiotics to address this challenge has not kept pace. Critical appraisal and drug development timelines in clinical phases made the task costly and tedious. Global pharmaceutical companies have withdrawn their attention, and only a limited number of companies are doing research and development in this field. The present review discusses the current scenario worldwide and introduces one health plan’s role in terms of the discovery of novel drugs and increased drug resistance.
Article Information
7
4285-4291
1009 KB
285
English
IJPSR
Kartikeya Tiwari
School of Paramedical and Allied Health Sciences, Al-Karim University (Previously Katihar Medical College), Katihar, Bihar, India.
kartikeya.tiwari@alkarimuniversity.edu.in
10 December 2022
26 March 2023
28 April 2023
10.13040/IJPSR.0975-8232.14(9).4285-91
01 September 2023
Download